Mal-PEG8-Phe-Lys-PAB-Exatecan

• UNSPSC Description:

  Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) composition[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC; Topoisomerase

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mal-peg8-phe-lys-pab-exatecan.html

• Solubility:

  DMSO : 180 mg/mL (ultrasonic)

• Smiles:

  O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(NC(C=C3)=CC=C3COC(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O

• Molecular Weight:

  1434.56

• References & Citations:

  [1]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2679821-44-2